Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Light and ion treatment to enhance medication efficacy in depression
ISRCTN10003823Phase 3Completed
- Sponsor
- University of British Columbia
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluoxetine in major depressive disorder (MDD) (4 arms), sponsored by University of British Columbia. Primary endpoint: Change in adjusted Hamilton Depression Rating Scale score. Started Sep 2009; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN10003823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10003823.